Allogene Therapeutics Inc (ALLO)
2.77
-0.24
(-7.97%)
USD |
NASDAQ |
May 17, 16:00
2.77
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Research and Development Expense (Annual): 242.91M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 242.91M |
| December 31, 2022 | 256.39M |
| December 31, 2021 | 220.18M |
| Date | Value |
|---|---|
| December 31, 2020 | 192.99M |
| December 31, 2019 | 144.54M |
| December 31, 2018 | 151.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
144.54M
Minimum
2019
256.39M
Maximum
2022
211.40M
Average
220.18M
Median
2021
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 34.29M |
| Vaxart Inc | 68.14M |
| Agenus Inc | -- |
| BioCryst Pharmaceuticals Inc | 216.57M |
| Stereotaxis Inc | 10.27M |